Ocular Therapeutix (OCUL)
(Real Time Quote from BATS)
$5.00 USD
-0.11 (-2.20%)
Updated Apr 23, 2024 12:54 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
OCUL 5.00 -0.11(-2.20%)
Will OCUL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for OCUL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OCUL
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
Wall Street Analysts Think Ocular Therapeutix (OCUL) Could Surge 34.74%: Read This Before Placing a Bet
OCUL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
Can VAALCO (EGY) Deliver Strong Q4 Earnings Performance?
Other News for OCUL
Optimistic Buy Rating for Ocular Therapeutix Amid Early-Stage NPDR Study and Wet AMD Potential
Why Super Micro Computer Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Ocular Therapeutix (OCUL)
Baird sees weakness in Ocular shares as "overdone"
What You Missed On Wall Street This Morning